Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phosphodiesterase type 5 inhibitors for erectile dysfunction.

Culley C Carson1, Tom F Lue

  • 1Department of Surgery, Division of Urology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Carson@med.unc.edu

BJU International
|July 27, 2005
PubMed
Summary

Phosphodiesterase type 5 inhibitors (PDE5Is) effectively treat erectile dysfunction (ED) by targeting the cyclic nucleotide pathway. New PDE5Is offer improved options for men with ED, enhancing treatment efficacy and patient candor.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects and mechanism of low-intensity pulsed ultrasounds on testicular steroidogenesis in rats.

Asian journal of andrology·2026
Same author

Amniotic fluid stem cell therapy improves erectile function in a diabetic rat model.

Andrology·2025
Same author

Exploring the Mechanisms of Microenergy Acoustic Pulse Therapy for the Treatment of Female Stress Urinary Incontinence-Part II.

Neurourology and urodynamics·2025
Same author

Reporting quality of animal research in journals that published the ARRIVE 1.0 or ARRIVE 2.0 guidelines: a cross-sectional analysis of 943 studies.

Cardiovascular diagnosis and therapy·2025
Same author

Microenergy shockwave therapies for female stress urinary incontinence.

Translational andrology and urology·2024
Same author

Regulating Tissue Growth Factors for Healing With Etherified Carboxymethylcellulose Matrix.

Journal of burn care & research : official publication of the American Burn Association·2024

Area of Science:

  • Pharmacology
  • Urology
  • Molecular Biology

Background:

  • The cyclic nucleotide signaling pathway, involving nitric oxide, is crucial for erectile function.
  • Dysregulation of this pathway contributes significantly to erectile dysfunction (ED) pathophysiology, often linked to chronic diseases.
  • Selective inhibition of phosphodiesterase type 5 (PDE-5) enhances erectile responses.

Purpose of the Study:

  • To review the role of PDE-5 inhibitors in treating erectile dysfunction.
  • To discuss the therapeutic advancements and clinical impact of PDE5Is.
  • To highlight the efficacy of sildenafil and newer agents like vardenafil and tadalafil.

Main Methods:

  • Review of scientific literature on PDE-5 inhibitors and erectile dysfunction.

Related Experiment Videos

  • Analysis of the mechanism of action of PDE5Is on the cyclic GMP pathway.
  • Clinical efficacy and tolerability data of available PDE5Is.

    • Main Results:

    • Sildenafil, a selective PDE5 inhibitor, has transformed ED treatment, proving effective across various severities and causes.
    • Newer PDE5Is, vardenafil and tadalafil, offer enhanced potency and pharmacokinetic profiles, respectively.
    • PDE5 inhibitors are well-tolerated and promote erectile responses to sexual stimulation.

    Conclusions:

    • PDE5 inhibitors are a cornerstone therapy for erectile dysfunction, offering significant clinical benefits.
    • Ongoing research into novel PDE5Is promises further improvements in ED management.
    • These therapies have improved treatment outcomes and patient quality of life.